SCHEMBL4920219

SCHEMBL4920219

CCC(CC)Oc1cccc(NC(=O)c2c[nH]nc2-c2cccs2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
RAB9A P51151 3/20 0.45
NPC1 O15118 2/20 0.45
KMT2A Q03164 8/20 0.43
MEN1 O00255 7/20 0.43
MAPT P10636 5/20 0.43
LMNA P02545 2/20 0.43
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.43
ALDH1A1 P00352 4/20 0.42
TP53 P04637 3/20 0.42
GAA P10253 2/20 0.42
USP2 O75604 1/20 0.42
ALOX15 P16050 1/20 0.42
HTT P42858 1/20 0.42
HSD17B10 Q99714 1/20 0.42
HPGD P15428 4/20 0.40
POLB P06746 1/20 0.40
KDM4E B2RXH2 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4911760 0.92 MEN1 (0.44) PLAUSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL4907618 0.88 MEN1 (0.43) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL4918087 0.88 MET (0.42) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL4918756 0.81 RXFP1 (0.46) PLAUMAPTKDM4ETHRB
SCHEMBL4922023 0.81 MEN1 (0.46) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL3639976 0.80 POLB (0.37) PLAUSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL4916251 0.75 MAPT (0.44) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL4919177 0.74 RXFP1 (0.46) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL3640392 0.73 POLB (0.36) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL6686183 0.72 NPC1 (0.55) RAB9ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 PLAU 4453/4885SMN1; SMN2 1228/4885RAB9A 2325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.